Novel Oral Drug Doubles Survival in Pancreatic Cancer Patients
A phase III trial shows daraxonrasib doubled overall survival vs chemotherapy in metastatic pancreatic cancer, signaling a new standard of care.
Summary
A new oral drug called daraxonrasib has shown remarkable results in treating previously treated metastatic pancreatic cancer. In the RASolute 302 phase III trial, patients taking daraxonrasib lived a median of 13.2 months compared to 6.6 months for those on standard chemotherapy — a doubling of survival. The drug works by blocking RAS signaling, a pathway mutated in over 90% of pancreatic cancers that has historically been considered undruggable. Presented at ASCO 2026 and published in the New England Journal of Medicine, these findings represent the first meaningful advance in second-line pancreatic cancer treatment in years. The FDA has already authorized an expanded access program, giving eligible patients early access while full approval is pursued.
Detailed Summary
Pancreatic cancer is one of the deadliest malignancies, with a five-year survival rate under 15%. Second-line treatment options after initial chemotherapy fails have been especially grim — until now. Results from the RASolute 302 phase III trial, presented at the ASCO 2026 annual meeting and simultaneously published in the New England Journal of Medicine, suggest a genuine turning point in how this disease can be treated.
The trial enrolled 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Patients were randomized to receive either daraxonrasib — an investigational oral RAS(ON) multi-selective inhibitor — or investigator's choice of chemotherapy. In the primary population of patients with RAS G12 mutations, daraxonrasib doubled both overall survival (13.2 vs 6.6 months) and progression-free survival (7.3 vs 3.5 months). Hazard ratios were strikingly favorable at 0.40 and 0.45 respectively, both highly statistically significant.
The drug works by binding to and blocking both wild-type and mutant RAS proteins, including the KRAS mutations — G12D, G12V, and G12R — found in the vast majority of pancreatic cancers. This approach addresses a signaling pathway long known to drive tumor growth but previously considered nearly impossible to drug effectively.
For clinicians and patients, the implications are substantial. ASCO's chief medical officer called the results a "grand slam," and leading oncologists confirmed daraxonrasib should be considered the new standard of care for second-line metastatic pancreatic cancer. The FDA has already approved an expanded access program, allowing some patients to access the drug before formal approval.
Caveats remain. Survival times, while dramatically improved, are still measured in months rather than years. The trial population was predominantly male, median age 65, and most had received prior first-line systemic therapy. Long-term data and broader real-world outcomes are still pending, and regulatory approval has not yet been granted.
Key Findings
- Daraxonrasib doubled overall survival vs chemotherapy: 13.2 months vs 6.6 months in RAS G12 patients
- Progression-free survival also doubled: 7.3 months vs 3.5 months with chemotherapy in the same population
- Drug targets RAS signaling pathway, mutated in over 90% of pancreatic cancer cases, previously seen as undruggable
- FDA authorized expanded access program in May 2026, enabling early patient access ahead of formal approval
- ASCO experts declared daraxonrasib the new second-line standard of care for metastatic pancreatic cancer
Methodology
This is a meeting coverage news report from MedPage Today based on phase III randomized controlled trial data presented at ASCO 2026. The findings were simultaneously published in the New England Journal of Medicine, a top-tier peer-reviewed journal, lending high credibility. The RASolute 302 trial enrolled 500 patients with clearly defined endpoints and statistically robust results.
Study Limitations
Full peer-reviewed publication details beyond the NEJM announcement have not been reviewed here; long-term survival and quality-of-life data are not yet available. The trial population skewed male and did not fully reflect all demographic groups. Formal FDA approval has not yet been granted, and real-world effectiveness may differ from controlled trial conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.